Registration & Co�ee

Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates

Neurotherapeutics-in-Development: The Next Five YearsChaired by: Harry Tracy, President, NI Research, Inc.Panelists: Darryle Schoepp, VP, Neuroscience, Merck & Co., Inc.David Bleakman, VP, CSO - Neuroscience Discovery Research, New York City, Eli Lilly and Co.Kees Been, Founder, President and CEO, Lysosomal Therapeutics, Inc.Todd Sherer, CEO, The Michael J. Fox Foundation

Bio Partnering & DealMaking PanelCo-Chaired by: Bruce Leuchter, Managing Director, PJT Partners Kiran Reddy, Venture Partner, Clarus Ventures, LLCPanelists: Carlos Buesa, CEO, Oryzon Genomics SADerek Small, President & CEO, Assembly BiosciencesIsaac Veinbergs, Head of External Innovation, Neurosciences, Sano�Martin Heidecker, Managing Director, Boehringer Ingelheim Venture Fund USA, Inc.Noelle Dubiansky, Partner, Goodwin Procter LLPSha�que Virani, Head of Neuroscience, Ophthalmology and Rare Diseases Partnering, F. Ho�mann La Roche Ltd.

07:30

08:20

08:50

09:30

PR Companies Track AModerated by: John Nolan, WBB Securities, LLC

ASDERA

Cantabio Pharmaceuticals, Inc.[OTCMKTS:LIOCD]

Purdue Pharma L.P.

Probiodrug AG[AMS:PBD]

ProMIS™ Neurosciences, Inc.[TSE:PMN]

M3 Biotechnology, Inc.

Co�ee Break10:10

Advances in Alzheimer’s Disease Panel Chaired by: Ryan Westphal, Sr. Director, Neuroscience Search & Evaluation, Eli Lilly and Co.Panelists: Eugene Williams, Executive Chairman, ProMIS™ Neurosciences, Inc.Hendrik Liebers, CFO, Probiodrug AGHoward Fillit, Founding Executive Director and CSO, The Alzheimer's Drug Discovery FoundationLeen Kawas, President & CEO, M3 Biotechnology, Inc.Murali Gopalakrishnan, Senior Director & Head, Search & Evaluation Neuroscience, AbbVie, Inc.

10:25

Rare & Orphan Diseases PanelChaired by: Mark Day, Head, CNS Virtual Discovery, Purdue Pharma L.P.Panelists:Allison Moore, Founder & CEO, Hereditary Neuropathy FoundationChaim Lebovits, CEO, BrainStorm Cell Therapeutics, Inc.Jak Knowles, Managing Director and VP Medical and Scienti�c A�airs, CureDuchenne VenturesLuca Benatti, CEO, Erydel SpAMarc Martinell, CEO, Minoryx Therapeutics S.L.

11:05

Neuropsychiatry & Pain Management PanelChaired by: Maxim Jacobs, Senior Healthcare Analyst, Edison Investment ResearchPanelists:Bob Linke, President & CEO, Embera NeuroTherapeutics, Inc.Gerhard Koenig, President & CEO, Quartet MedicineJonathan Javitt, CEO, NeuroRx, Inc.Wayne Drevets, VP, Disease Area Leader in Mood Disorders, Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson, Inc.

11:35

Keynote Speech: “Neuroscience in a Time of Uncertainty” by Harry Tracy, President, NI Research, Inc.08:30

Networking Lunch12:15

10:25

10:45

11:05

11:25

11:45

12:05

Keynote Speech: “A Regenerative Approach to Neurodegenerative Diseases” by Dr. Daniel Alkon, President and CSO, Neurotrope Bioscience, Inc.13:15

PR Companies Track BModerated by: Emad Samad, WBB Securities, LLC

Advances in Parkinson’s Disease & Other Movement Disorders PanelChaired by: Ginger Johnson, CEO, De�ned Health, a Cello Health businessPanelists:Alexander Breidenbach, Director, Global BD Neuroscience, F. Ho�mann-La Roche Ltd.David Donabedian, Co-Founder and CEO, Axial BiotherapeuticsJon Kaiser, CEO, K-PAX Pharmaceuticals, Inc.Kees Been, Founder, President and CEO, Lysosomal Therapeutics, Inc.Kenneth Rhodes, CSO, Yumanity Therapeutics

13:3513:35 Nexeon Medsystems, Inc.

13:45 SalubRx Therapeutics, Inc.

13:55 Pharmasum Therapeutics AS

14:05 vasopharm GmbH

14:15 T3D Therapeutics, Inc.

14:25 EryDel SpA

14:35 Minoryx Therapeutics S.L.

14:45 K-PAX Pharmaceuticals, Inc.

PR Companies Track DModerated by: Leonard Sachs, Sachs Associates

15:10 Exscientia Ltd.

15:20 NeuroRx, Inc.

15:40 Embera NeuroTherapeutics, Inc.

16:00 Quartet Medicine

PR Companies Track CModerated by: Robert Wotczak, Wotczak Group

Co�ee Break16:20

Investor RoundtableChaired by: Steve Dickman, CEO, CBT AdvisorsPanelists:Daniel O’Connell, Investment Manager, Arix BioscienceJason Park, Principal, Flagship VenturesKristen Kosofsky, Sr. Managing Director, Hercules Technology Growth Capital, Inc.Vincent Miles, Partner, Abingworth LLP

16:35

Networking Reception17:20

End of the 2 NBPI Forum18:30

14:20

14:40

15:00

15:20

15:40

Brainstorm Cell Therapeutics, Inc.[NASDAQ:BCLI]

Oryzon Genomics SA[BME:ORY]

Neurotrope Bioscience, Inc. [OTCQB:NTRP]

KemPharm, Inc.[NASDAQ:KMPH]

SunRegen Healthcare AG

Networking Lunch12:15

nd